Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorDeveci, Burak
dc.contributor.authorDöşemeci, Levent
dc.contributor.authorAslan, Ayşe
dc.contributor.authorAsal, Gökhan
dc.contributor.authorÜstün, Bilge
dc.contributor.authorYıldırımer Akar, Meltem
dc.contributor.authorToptaş, Tayfur
dc.contributor.authorYavuz Taşlıpınar, Mine
dc.contributor.authorSaba, Rabin
dc.date.accessioned2024-01-04T16:00:16Z
dc.date.available2024-01-04T16:00:16Z
dc.date.issued2022en_US
dc.identifier.issn2149-3189
dc.identifier.urihttps://hdl.handle.net/11363/6855
dc.description.abstractObjectives: Patients with hematological disorders are often immunosuppressive due to underlying diseases, immunosuppressive therapies or cytotoxic chemotherapeutics. In the case of coronavirus disease 2019 (COVID19), they are at high risk of poor prognosis. Therefore, the present study aimed to evaluate the determinants of clinical course and mortality in COVID-19 patients with hematological disorders. Methods: Sixty-two hospitalized patients older than 18 years with documented COVID-19 and hematological disorders were included in the study. The clinical and laboratory data of the patients were recorded. Age, gender, overall follow-up time, duration of hospitalization, neutropenia, D-dimer levels, disease status, presence of underlying diseases, prior autologous and allogeneic stem cell transplant, immunosuppressive drug use, chemotherapy within 28 days, pneumonia, secondary bacterial infection, intubation, survival and mortality of the patients were evaluated. Results: Twenty-eight (45.2%) of 62 patients died due to COVID-19 and its complications. It was observed that presence of pneumonia, secondary bacterial infection, intubation, neutropenia developed after the diagnosis of COVID-19, and elevated D-dimer levels were associated with significant mortality. A D-dimer level of > 1.2 µg/dL was found to be associated with 5.02 fold increase in the risk of death, with 60.7% sensitivity and 76.5% specificity. Presence of rheumatologic diseases also affected survival negatively. Conclusions: D-dimer levels have high predictive value for mortality. Considering the identified risk factors, it can be concluded that broad spectrum antibiotics can be administered earlier for prevention of high mortality rates in COVID-19 patients with underlying hematological disorders. These observations can give confidence to clinicians that delivery of effective anticancer regimens should continue during this difficult pandemic.en_US
dc.language.isoengen_US
dc.publisherPrusa Medical Publishingen_US
dc.relation.isversionof10.18621/eurj.1000067en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectHematological disordersen_US
dc.subjectMortalityen_US
dc.titleDeterminants of clinical course and mortality in COVID19 patients with hematological disorders: real life data from a single centeren_US
dc.typearticleen_US
dc.relation.ispartofThe European Research Journalen_US
dc.departmentSağlık Bilimleri Fakültesien_US
dc.authoridhttps://orcid.org/0000-0001-5820-1903en_US
dc.identifier.volume8en_US
dc.identifier.issue4en_US
dc.identifier.startpage450en_US
dc.identifier.endpage461en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.institutionauthorDeveci, Burak


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster